GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of GUJARAT THEMIS BIOSYN LTD. stock ₹69.74, price ₹389, that is 82.1% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
GUJARAT THEMIS BIOSYN LTD.
GUJTHEM · BSEFar too expensive (fair value 82% below the price), company just short of the bar and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range ₹32.27 – ₹472.70 · fair‑value band ₹49.29 – ₹90.18 · the ₹389.25 price screens above the ₹69.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether GUJARAT THEMIS BIOSYN is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin.
Show moreShow less
The company was incorporated in 1981 and is based in Mumbai, India.
Stock analysis
GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) currently trades at ₹389.25, while our model-based Fair Value estimate is ₹69.74, 82% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹70.42 per share, and 0 of the 16 models we run sit above the ₹389.25 price.
Bear case: the Asset-Based group reads lowest at ₹14.81, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹49.29 (bear) to ₹90.18 (bull), the price of ₹389.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
GUJARAT THEMIS BIOSYN LTD. reported revenue of ₹1.7B in FY2026 versus ₹1.1B in FY2022, a compound +9.8%/yr. Reported net income was ₹467M in FY2026, compounding +1.7%/yr from FY2022.
Key figures
Market cap ₹50.3B (≈ $533M) Small · P/E ratio 87.1 · P/S ratio 28.9 · EPS (TTM) ₹4.47 · Dividend yield 0.2% · Net margin 28.0% · Return on equity 17.4% · Return on assets (EBIT) 31.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −82%, GUJTHEM screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
GUJTHEM screens overvalued: fair value 82% below the price. Compare with Merck KGaA →
Compare GUJARAT THEMIS BIOSYN LTD. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs GUJTHEM |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs GUJTHEM |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs GUJTHEM |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs GUJTHEM |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs GUJTHEM |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs GUJTHEM |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs GUJTHEM |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs GUJTHEM |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs GUJTHEM |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs GUJTHEM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) overvalued or undervalued?
What is the fair value of GUJTHEM?
What is the quality score of GUJTHEM?
What is the price target for GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the GUJARAT THEMIS BIOSYN LTD. stock forecast for 2026?
What is the revenue of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Does GUJARAT THEMIS BIOSYN LTD. pay a dividend?
How much is the dividend of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) and when is the ex-dividend date?
What is the intrinsic value of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
Is GUJARAT THEMIS BIOSYN LTD. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GUJTHEM?
How much is GUJARAT THEMIS BIOSYN LTD. worth?
What do the bullish and bearish scenarios say about GUJTHEM?
What is the P/E ratio of GUJTHEM?
How solid is the balance sheet of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
How far is GUJTHEM from its 52-week high?
Which stocks are comparable to GUJARAT THEMIS BIOSYN LTD.?
Is GUJARAT THEMIS BIOSYN LTD. stock attractive at the current price?
How is the fair value of GUJTHEM calculated?
Is it still worth investing in stocks now?
What is the share price of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What should I pay attention to with GUJARAT THEMIS BIOSYN LTD. right now?
Key figures of GUJARAT THEMIS BIOSYN LTD.
How large is the market capitalisation of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the P/S ratio of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What are the earnings per share of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the dividend yield of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the net margin of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the return on equity of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the EBIT return on assets of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
What is the operating margin of GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
How fast is revenue growing at GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
How fast are earnings growing at GUJARAT THEMIS BIOSYN LTD. (GUJTHEM)?
How much free cash flow does GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) generate?
How much net debt does GUJARAT THEMIS BIOSYN LTD. (GUJTHEM) carry?
Watch GUJARAT THEMIS BIOSYN LTD. in the live analysis
One click puts GUJARAT THEMIS BIOSYN LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.